151 related articles for article (PubMed ID: 10796851)
1. Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults.
Darbyshire J; Foulkes M; Peto R; Duncan W; Babiker A; Collins R; Hughes M; Peto T; Walker A
Cochrane Database Syst Rev; 2000; 2000(2):CD002038. PubMed ID: 10796851
[TBL] [Abstract][Full Text] [Related]
2. Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults.
Darbyshire J; Foulkes M; Peto R; Duncan W; Babiker A; Collins R; Hughes M; Peto T; Walker A
Cochrane Database Syst Rev; 2000; (3):CD002038. PubMed ID: 10908523
[TBL] [Abstract][Full Text] [Related]
3. Immediate versus deferred zidovudine (AZT) in asymptomatic or mildly symptomatic HIV infected adults.
Darbyshire J; Foulkes M; Peto R; Duncan W; Babiker A; Collins R; Hughes M; Peto T; Walker A
Cochrane Database Syst Rev; 2000; (3):CD002039. PubMed ID: 10908524
[TBL] [Abstract][Full Text] [Related]
4. Immediate versus deferred zidovudine (AZT) in asymptomatic or mildly symptomatic HIV infected adults.
Darbyshire J; Foulkes M; Peto R; Duncan W; Babiker A; Collins R; Hughes M; Peto T; Walker A
Cochrane Database Syst Rev; 2000; (2):CD002039. PubMed ID: 10796852
[TBL] [Abstract][Full Text] [Related]
5. Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: meta-analyses of the randomised evidence. HIV Trialists' Collaborative Group.
Lancet; 1999 Jun; 353(9169):2014-25. PubMed ID: 10376616
[TBL] [Abstract][Full Text] [Related]
6. Studies of zidovudine in combination with didanosine and zalcitabine.
Jablonowski H
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S52-6. PubMed ID: 8595509
[TBL] [Abstract][Full Text] [Related]
7. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee.
Lancet; 1996 Aug; 348(9023):283-91. PubMed ID: 8709686
[TBL] [Abstract][Full Text] [Related]
8. Evidence for prolonged clinical benefit from initial combination antiretroviral therapy: Delta extended follow-up.
Delta Coordinating Committee
HIV Med; 2001 Jul; 2(3):181-8. PubMed ID: 11737399
[TBL] [Abstract][Full Text] [Related]
9. Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells.
Benbrik E; Chariot P; Bonavaud S; Ammi-Saïd M; Frisdal E; Rey C; Gherardi R; Barlovatz-Meimon G
J Neurol Sci; 1997 Jul; 149(1):19-25. PubMed ID: 9168161
[TBL] [Abstract][Full Text] [Related]
10. ddI and d4T plus protease inhibitors.
GMHC Treat Issues; 1996 Nov; 10(11):8-9. PubMed ID: 11364012
[TBL] [Abstract][Full Text] [Related]
11. Major study shows AZT monotherapy inferior.
James JS
AIDS Treat News; 1995 Sep; (no 231):3-4. PubMed ID: 11362867
[TBL] [Abstract][Full Text] [Related]
12. Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
Albrecht MA; Hughes MD; Liou SH; Katzenstein DA; Murphy R; Balfour HH; Para MF; Valdez H; Hammer SM;
AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1337-44. PubMed ID: 11018853
[TBL] [Abstract][Full Text] [Related]
13. ACTG 175 and Delta.
Torres G
GMHC Treat Issues; 1995 Oct; 9(10):2-3. PubMed ID: 11362915
[TBL] [Abstract][Full Text] [Related]
14. Antiretroviral combination treatment prolongs life in people with HIV/AIDS.
Cooper EC
AMFAR Rep; 1996 Jan; ():1-5. PubMed ID: 11363617
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with ZDV + DDI versus ZDV + DDC in patients with progression of HIV-infection under treatment with ZDV.
Mauss S; Adams O; Willers R; Jablonowski H
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Apr; 11(5):469-77. PubMed ID: 8605592
[TBL] [Abstract][Full Text] [Related]
16. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group.
Larder BA; Kohli A; Bloor S; Kemp SD; Harrigan PR; Schooley RT; Lange JM; Pennington KN; St Clair MH
J Virol; 1996 Sep; 70(9):5922-9. PubMed ID: 8709213
[TBL] [Abstract][Full Text] [Related]
17. ACTG 175: new insights into treating patients with intermediate-stage HIV disease.
Folkers G
NIAID AIDS Agenda; 1995 Dec; ():4-5. PubMed ID: 11363352
[TBL] [Abstract][Full Text] [Related]
18. A comparison of zidovudine, didanosine, zalcitabine and no antiretroviral therapy in patients with advanced HIV disease.
Torres RA; Barr MR; McIntyre KI; Thornton JR; Shay WM; Feldman RD; George NJ; Britton DJ
Int J STD AIDS; 1995; 6(1):19-26. PubMed ID: 7727578
[TBL] [Abstract][Full Text] [Related]
19. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS.
Saravolatz LD; Winslow DL; Collins G; Hodges JS; Pettinelli C; Stein DS; Markowitz N; Reves R; Loveless MO; Crane L; Thompson M; Abrams D
N Engl J Med; 1996 Oct; 335(15):1099-106. PubMed ID: 8813040
[TBL] [Abstract][Full Text] [Related]
20. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.
Hammer SM; Katzenstein DA; Hughes MD; Gundacker H; Schooley RT; Haubrich RH; Henry WK; Lederman MM; Phair JP; Niu M; Hirsch MS; Merigan TC
N Engl J Med; 1996 Oct; 335(15):1081-90. PubMed ID: 8813038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
